Bright Minds Biosciences is a pre-clinical biosciences company that develops selective 5-HT receptor agonists to treat patients with severe and life-altering diseases such as epilepsy, pain, and neuropsychiatry. They have partnerships with National Institutes of Health, University of Texas Medical Branch, and Medical College of Wisconsin. The company was founded in 2019 and is headquartered in Vancouver, Canada.